Taking the next step in PARP-inhibitor clinical trials in older women with ovarian cancer – Staging the aging

• Older patients are still underrepresented in randomized controlled clinical trials. • Older patients receiving PARP-inhibitors tend to achieve shorter PFS, even those considered fit. • Older patients experience more side effects, than their younger counterparts. • Prospective “real-world” data is...

Descripción completa

Detalles Bibliográficos
Autores principales: Liposits, G., Lichtman, S.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846923/
https://www.ncbi.nlm.nih.gov/pubmed/33553556
http://dx.doi.org/10.1016/j.gore.2021.100710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846923/
https://www.ncbi.nlm.nih.gov/pubmed/33553556
http://dx.doi.org/10.1016/j.gore.2021.100710

Ejemplares similares